← Back to patent-cliff list
盐酸去氧肾上腺素
Tier C — Watch / tradePhenylephrine Hydrochloride
-
Originator
1955
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：ADRA1
Brand：Mydfrin、Alcon Efrin、Incostop、Nostril、Efrin、Biomydrin、Vazculep、Neo-Synephrine hydrochloride
Indications (approved)：瞳孔散大、低血压、睫状肌麻痹、室上性心动过速、休克
Regional status
US
批准上市
2012-12-20
EU
终止
2007-02-01
China
批准上市
1995-01-01
Japan
批准上市
1955-01-01
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Phenylephrine Hydrochloride?
Approved indications include: 瞳孔散大, 低血压, 睫状肌麻痹, 室上性心动过速, 休克.
When does the Phenylephrine Hydrochloride patent expire?
No public expiry year is available for Phenylephrine Hydrochloride yet; this page updates once verified.
How do I get a quote for Phenylephrine Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-25